The Psychedelic Therapy Podcast22 Sep 2021

Joseph Mays (Chacruna): Conservation and Indigenous Reciprocity

As the Psychedelic Renaissance blossoms, many healers and business leaders are rightly looking at environmental conservation and reciprocity with Indigenous wisdom keepers. Joseph Mays is Program Director for the Chacruna's new Indigenous Reciprocity Initiative (IRI). On the podcast, he shares some powerful ways for the psychedelic community to cultivate a healthy relationship with Indigenous people in the Americas.

On the show, we discuss the Indigenous worldview as it pertains to psychedelic healing. We learn about Chacruna’s Ayahuasca Community Committee on which Joe sits and consider what well-meaning people might get wrong about reciprocity. Joseph explains the details of the Indigenous Reciprocity Initiative and its successes so far. Finally we discuss what it means to use interest in psychedelics to raise funds for effective altruism.

Joseph Mays is an Ethnobotanist, a researcher and a writer. He is the program director of Chacruna’s Indigenous Reciprocity Initiative where he conducts research and builds connections with small Indigenous communities throughout the Americas to support Chacruna’s mission of increasing cultural reciprocity in the psychedelic space.

If you’d like to go deeper on this subject, join us for Maya's first collaborative event to raise awareness and funding for IRI on Wednesday, September 22. Donate by registering for the event.

Links

Timestamps

:09 - Indigenous understanding invites you to step into a relationship
:14 - Chacruna and the Ayahuasca Community Committee
:17 - IRI, the Indigenous Reciprocity Initiative
:23 - What well-meaning people get wrong about indigenous reciprocity
:32 - Successes of the fund after its first quarter
:44 - Using interest in psychedelics to raise funds
:51 - Joseph speaks to psychedelic practitioners

Denne episoden er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(64)

Ismail Lourido Ali (MAPS): The Work No Executive Order Can Do

"We can pass 10 executive orders. We can put $500 million for drug development. And if we don't have people who are willing to hold that space... we're not going to get anywhere." - Ismail Lourido Ali...

21 Apr 1h 10min

Robin Arnott & Sandeep Prakash: Training for Psychedelic Surrender

Can we practice the art of surrender before the first dose?Today on the show Robin Arnott and Dr. Sandeep Prakash explain how SoundSelf evolved from a VR curiosity into a clinically oriented tool that...

25 Apr 202555min

Joshua White: Who You Gonna Call? Fireside

Imagine you’re in the middle of a psychedelic journey—things are getting intense, and you just need someone to talk to. That’s whereFireside Project comes in. As the world’s first psychedelic peer sup...

13 Feb 20251h 14min

Tom Feegel: Ibogaine for Cognitive Enhancement

A month ago, I had the privilege of visiting Beond in Cancun, Mexico to experience an ibogaine treatment for cognitive enhancement. Today, I’m joined by Beond CEO Tom Feegel to discuss how this remark...

27 Jan 20251h 6min

Juan Pablo Capello: A Wakeup Call for Ketamine Telehealth Companies

Today, I’m joined by Juan Pablo Capello, co-founder and former CEO of New Life Health, a telehealth ketamine therapy service launched in 2021. Juan Pablo has raised concerns about low standards of car...

20 Nov 20241h 4min

Natalie Lyla Ginsberg (MAPS): The FDA, MDMA, and the Future of Psychedelic Therapy

Today, we’re exploring a critical issue facing the field of psychedelic medicine: the recent FDA rejection of MAPS’ clinical trials to reschedule MDMA for therapeutic use. This setback affects many of...

28 Okt 20241h 3min

Tricia Eastman & Joseph Barsuglia: Ibogaine is Miracle Grow for the Brain

Today we’re doing something a little different. I’m re-releasing an episode from my personal podcast, Life is a Festival, because it remains one of my favorite interviews ever. This conversation, orig...

18 Okt 20241h 9min

Jennifer Tippett: Understanding Private Practice vs Clinical Trials

After the shocking decision of an advisory committee recommendation that the FDA reject MDMA as a treatment for post-traumatic stress disorder, I wanted to speak to someone who understands the differe...

8 Aug 202446min